We recently published a list of 12 Best Metaverse Stocks to Invest in. In this article, we are going to take a look at where ...

The S&P 500 ticked 0.1% higher on Thursday, April 17, wrapping up a shortened week that focused on earnings and the Federal ...

US stocks end a choppy day mixed. Intel warns of chip sales licenses. Trump calls for lower rates. UnitedHealth posts weak ...

Learn more about whether UiPath Inc. or Pegasystems Inc. is a better investment based on AAII's A+ Investor grades, which ...

Learn more about whether UiPath Inc. or SoundHound AI, Inc. is a better investment based on AAII's A+ Investor grades, which ...

Morgan Stanley analyst Sanjit Singh maintained a Hold rating on UiPath (PATH – Research Report) today and set a price target of $12.00.Stay ...

Visa also continually rolls out new products that deliver benefits to customers, vendors, and merchants. Earlier in April, ...

UiPath (PATH) closed the most recent trading day at $10.71, moving -1.47% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 0.79%. Elsewhere, the Dow ...

Cathie Wood's Ark Invest sold shares in UiPath, Prime Medicine, and Repare Therapeutics, with notable gains and losses.

UiPath (PATH) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Despite a 20% stock decline, we maintain a bullish view on UiPath due to its strategic pivot to Agentic AI and strong ...

UiPath shares rise on launch of generative AI-based UiPath Medical Record Summarization agent at Google Cloud Next 2025.